期刊文献+

罗库溴铵TCI用于腹部手术患者的有效浓度探讨

A study of the optimum concentration of rocuronium for target controlled infusion in patients′operation on abdominal region
下载PDF
导出
摘要 目的探讨腹部手术患者罗库溴铵靶控输注的有效维持浓度。方法60例ASAⅡ级、择期全麻腹部手术患者,随机分成A、B、C三组,每组20例。根据预实验结果,将三组诱导插管时效应室靶浓度(Ce)均设置为3μg/ml,术中维持Ce分别为0.6、0.8、1.0μg/ml。观察各组诱导插管、术中肌松维持和术后肌松恢复情况。结果三组均可顺利完成气管插管;术中肌松维持,0.6μg/ml组(A组)肌松满意率低,0.8μg/ml组(B组)和1.0μg/ml组(C组)均可维持满意肌松,但1.0μg/ml组罗库溴铵用量更大、术中肌肉阻滞程度较深、术后恢复时间延长(P<0.05)。结论腹部手术患者诱导插管时罗库溴铵Ce设置为3μg/ml、术中Ce维持在0.8μg/ml,可以实现诱导插管顺利、术中肌松满意和术毕迅速恢复的目的。 Objective To investigate the optimum concentration of rocuronium for target controlled infusion (TCI) infusion in patients'operation on abdominal region. Methods Sixty patients(ASA grade Ⅱ )scheduled for operation on abdominal region under general anesthesia were studied. The patients were randomly divided into three groups, A, B and C, with 20 cases in each group. The target effective site concentration (Ce) of rocuronium for intubation was 3 μg/ml in each group, and the Ce during operation were O. 6,0.8 and 1.0 μg/ml in A, B and C group respectively. Results Suc- cessful intubation condition was obtained in three groups. Neuromuscular blockade during operation was satisfactory in B and C groups, but not in group A. The Rocuronium consumption, muscle relaxation during surgery and recovery time to 25% of T1 of C group were more than those in group B (P 〈 0.05). Conclusions The dosage regimen of group B is more suitable for patients'operation on abdominal region.
作者 张凯 岳修勤
出处 《医学信息(内.外科版)》 2009年第8期691-693,共3页 Medical Information Operations Sciences Fascicule
关键词 雄甾烷醇类 药物投予系统 药效动力学 androstanols drug delivery systems pharmacodynamics
  • 相关文献

参考文献6

二级参考文献15

  • 1Khalil MD, Honneur G, Duvaldestin P, et al. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis.Anesthesiology, 1994,80:1241-1247.
  • 2Servin FS, Lavaut E, Kleef U, et al. Repeated doses of rocuronium bromide administered to cirrhotic and control patients receivingi soflurane. Anesthesiology, 1996, 84: 1092-1100.
  • 3Savarese JJ, Caldwell J-E, Lien CA, et al. Pharmacology of muscle relaxants and their antagonists. In: Miller RD, ed. Anasthesia. 5th edn.New York: Churchill Livingstone, 2000. 412-490.
  • 4Miert MMV, Eastwood NB, Boyd AH, et al. The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. Br J Clin Pharmacol, 1997, 44: 139-144.
  • 5Wierda J-MKH, Proost JH, Schiere S, et al. Pharmacokinetics and pharmacokinetic/dynamic relationship of rocuronium bromide in humans. Eur J Anaesth, 1994, 11: 66-74.
  • 6Bevan DE. Rocuronium bromide and organ failure. Eur J Anaesth,1994,11: 87-91.
  • 7Cooper RA, Maddineni VR, Mirakhur RK, et al. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide(Org 9426) during isoflurane anesthesia in patients with and without renal failure.Br J Anaesth,1993,71:222-226.
  • 8Ma H, Zhuang X. Selecting of neuromuscular blocking agents in patients undergoing renal transplantation under general anesthesia. Chin Med J ,2002,115:1692-1696.
  • 9Khuenl-Brady KS, Pomaroli A, Puhringer F, et al. The use of rocu-ronium (ORG 9426) in patients with chronic renal failure. Anaesthesia,1993,48:873-875.
  • 10Proost JH, Eriksson LI, Mirakhur RK, et al. Urinary, biliary and faecal excretion of rocuronium in humans. Br J Anaesth,2000,85:717-723.

共引文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部